فعالیتهای تحقیقاتی دکتر علی بدیعی

امتیاز کاربران

ستاره غیر فعالستاره غیر فعالستاره غیر فعالستاره غیر فعالستاره غیر فعال
 

Curriculum Vitae

 

Name: Ali

Surname: Badiee

Date of birth: 20. 09. 1975

Marital status: Married

E-mail: Badieeaاین آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید ; این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

P.O.Box: 91775-1365

Phone: +98-51-31801339

Fax: +98-51-38823251

 


Education:

1- Visiting Scholar: Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA (2014-2015)

2- Ph.D. in Pharmaceutics: School of Pharmacy, Mashhad University of Medical Science, Iran (2001-2006)

3- Research fellowship: School of Pharmacy/ Mater Medical Research Institute, University of Queensland, Australia. (Mar 2005-Nov 2005)

4- Pharm. D: School of Pharmacy, Mashhad University of Medical Science, Iran (1993 -1999)


Academic and Professional Positions Held:

1- Associate Professor: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad-Iran (04/2013- present)

2- Assistant Professor: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad-Iran (10/2008- 04/2013)

3- Researcher: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran-Iran (1/2008- 10/2008)

4- Lecturer: School of Pharmacy, Zabol University of Medical Sciences, Zabol-Iran (2007-2008)


Technical Skills:

1- Commonly used immunological techniques for antigen processing and presentation (Flow cytometry, Fluorescence Microscopy, ELISpots, ELISA, Extra- or Intra-cellular cytokine Assay, Western blotting, IHC staining)

2- Analytical Instrument experiences (Size exclusion Chromatography, TLC, IR, UV-vis, Particle size Analyzer, Spectrofluorometry, Electrophoresis)

3- Preparation techniques for lipid-based particulate drug/vaccine delivery systems such as Liposomes, Immunoliposomes, Virosomes, ISCOMs, and LPD (Lipid Film method with Extrusion, Detergent removal, DRV, Ethanol Injection)

4- Care and Handling of Laboratory mice and rabbit

5- General cell culture techniques and parasite burden in animal tissue

6- Biostatistical methods for data analysis


Teaching Experiences:

1- Tumor Targeted Drug Delivery Systems, Vaccine Delivery systems, New Drug Approval Process & Clinical Trial Design, DNA Vaccines, Nanoparticles’ biodistribution, and Quality Control of Vaccines.

2- Pharmacy practice and Basic pharmacology.


Training Courses and Workshops:

1- Introduction to ICH/CTD guidance, 2012

2- Introduction to Standard Operating Procedures (SOP) for pharmaceutical compounds, 2012.

3- Introduction to intellectual property and patent search, 2011.

4- Introduction to research and research methods, 2010.

5- Scientific articles writing and publishing methods, 2010.

6- Overview of vaccine products and their quality controls, 2010.

7-Introduction to Whole animal body imaging, 2010.

8- Introduction to particle size analysis (PSA), 2009.

9- Introduction to atomic force microscopy (AFM), 2009.

10- Microsoft Word, Power Point, Excel, Outlook, SPSS, InStat, and GraphPad Prism, 2009.

11- Good Clinical Practice, 2009.

12- Biosafety practices and vaccine production, 2009.

13- Introduction to medical digital library resources, 2008.

14- Basic pharmacokinetic-pharmacodynamics in drug development, 2003.


Review for Journals:

1- International Journal of Biological Macromolecules

2- Oncotarget journal

3- Journal of Nanotechnology: Nanomedicine & Nanobiotechnology

4- Vaccine journal

5- Iranian Journal of Pharmaceutical Research

6- Iranian Journal of Basic Medical Sciences


Membership:

1-Editorial board, Nanomedicine Journal, since 2012.

2- Director of MUMS Pharmaceutical Technology Incubator, 2011-2014.

3- Member of Nanotechnology Research Center of MUMS, since 2009.

4- Member of Iranian Medical Council since 2000.


Honors & Awards:

1- Best PhD dissertation, 11th Iranian seminar of pharmaceutical scientists, Iran, 2008 (Offered by Iranian association of pharmaceutical scientists).

2- Ranked second in modern technology, 13th Razi Research Festival on Medical Sciences, Iran, 2007.

3- A six-month scholarship awarded by Iranian Ministry of Health and Medical Education in UQ, Australia, 2005.

Research Interests:

1- Liposomal vaccine/drug delivery systems

2-Drug, Protein, or Peptide formulations

3- Lipid based nanoparticles as immunoadjuvants


Current Research:

1-Chemoimmunotherapy against Leishmaniasis or cancer with lipid based nanoparticles


Ph. D.& Pharm. D. Dissertations Completed under Mentorship:

Ph. D.

1- Ahmad Mehravaran, Formulation, physicochemical characterization and evaluation of induced immune response with ISCOM nanoparticles containing Leishmania antigens in murine model (2013-2015).

2- Seyedeh Alia Moosavian, Formulation and characterization of nanoliposomal doxorubicin targeted with anti- Her-2/neu aptamer and evaluation of their anti tumor effects in vitro and in vivo in mice bearing Her-2/neu expressing breast cancer (2012-2015).

3- Mercedeh Mansourian, Preparation and characterization of positively charged fusogenic liposomes containing  Her2  peptides and MPL or CpG-ODN adjuvant  as   a vaccine against breast cancer and evaluation of generated immune response  in mice model (2012-2015).

4- Mahnaz Nourbakhsh, Evaluation of effects of nanolipoparticles containing MDR1 siRNA on drug resistance in doxorubicin resistant breast cancer cells (MCF-7/Adr) (2011-2014).

5- Omid Chavoshian, Formulation and physicochemical characterization of virosomes containing Leishmania antigens and evaluation of induced immune response in murine model (2010- 2013 ).

6- Amir Hossein Sahebkar, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction (2010-2013).

7-Mohammad Reza Amin, Formulation and characterization of nanoliposomal doxorubicin prepared with DChemsPC or DShemsPC and targeted with RGD peptides, and in vitro/in vivo evaluation of their anti tumor effects in mice bearing C26 colon carcinoma tumor (2009- 2013 ).

Pharm. D.

1- Fatemeh Fazaeli, Optimization of preparation method for nanoliposomal soluble Leishmania antigens and characterization of their physicochemical properties (2012-2015).

2- Sara Shokohh Saremi, In vitro uptake evaluation of different nanoliposome formulations containing soluble leishmania antigens by bone marrow-derived dendritic cells of C57BL/6 mice (2013-2014).

3-Maryam Shahriari, In vitro uptake evaluation of different nanoliposome formulations containing soluble leishmania antigens by bone marrow-derived dendritic cells of BALB/c mice (2013-2014).

4-Alireza komeilinezhad, Preparation and characterization of ISCOMATRIX nanoparticles (2012-2013).

5-Zahra Mohammaddamini, in vivo evaluation of immunoadjuvant potential of iscomatrix when co-administered with PR8 influenza virus (2012-2013).

6- Arezoo Sobhani, Formulation and characterization of nanoliposomal doxorubicin targeted with sphingomyelin and evaluation of their citotoxicity effects, in vitro on C26 colon carcinoma tumor (2012-2013).

7- Laleh Naghibi, Formulation and characterization of a conjugated Her2 peptide (P435+P5) nanoliposomes containing MPL adjuvant as a vaccine against breast cancer and evaluation of their immune responses and anti tumor effects in murine model  (2012-2014)

8- Niloofar Farzad, Formulation and characterization of a conjugated Her2 peptide (P435) nanoliposomes containing MPL adjuvant as a vaccine against breast cancer and evaluation of their immune responses and anti tumor effects in murine model  (2012-2014)

9- Razieh Ghoorchian, Preparation, physicochemical properties assay and in vitro evaluation of targeting efficiency of nanoliposomes containing Leishmania antigens to human dendritic cells (2012-2013).

10- Hamed Eshaghian, In vitro evaluation of targeting efficiency of nanoimmunoliposomes containing Leishmania antigen to human dendritic cells (2012-2013).

11- Mahsa Bagheri, Formulation and characterization of nanoliposomal doxorubicin targeted with Tat peptide and evaluation of their antitumor effects in vitro and in vivo on C-26 colon carcinoma cell line (2012-2013).

12- Ghazal Alipour Talesh, Preparation of nanoliposomes containing Her2 peptide and Poly(I:C) adjuvant as vaccine against breast cancer and evaluation of their immunological  response and anti tummor effects (2013-2014).

13- Amir Hossein Sabbaghi, Preparation and characterization of chitosan and trimethylchitosan nanoparticles loaded with influenza virus, with or without alginate coat, for nasal immunization to mouse (2012-2013).

14- Seyede Shima Mirkazemi, Preparation and study of physicochemical properties of nanoliposomes containing soluble leishmania antigens and MPL adjuvant (2010-2011).

15- Iman jaafari, Preparation, characterization, and evaluation of induced immune response by nanoliposomes containing whole Leishmania lysate antigens in a mouse model (2010-2011).

16- Hesamoddine Hosseinjani, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with cationic nanoliposomes containing CpG ODN (2009-2010).

17- Hadi Naseri, Evaluation of using PEG polymer on physicochemical and generated immune response properties of cationic liposomes containing soluble Leishmania antigens (2010-2011).

18- Mahdieh Morakkabi, Preparation, characterization, and evaluation of induced immune response by nanoliposomes containing whole Leishmania lysate antigen with MPL in a mouse model (2011-2012).

19- Zahra Akbari Nooghabi, Preparation, characterization, and evaluation of induced immune response by positively charged nanoliposomes containing soluble Leishmania antigens in mouse model of Leishmania (2011-2012).

20- Fatemeh Fakhraee pishbaghan, Preparation and characterization of LPD-nanoparticles containing rgp63 and rLmaC1N and evaluation of immune response stimulation against leishmaniasis in murine model (2010-2012).

21- Nazanin Biari, Preparation, characterization, and evaluation of induced immune response by sphingomyelin nanoliposomes containing whole Leishmania lysate antigen with MPL in a mouse model (2010-2012).

22- Faeze Eskandari, Evaluation of protection rate and immune response against nanoliposomes containing Leishmania antigen in murine model (2010-2011).

23- Zohreh Taziki, Formulation and characterization of nanoliposomal doxorubicin targeted with TAT peptides and evaluation of their antitumor effects, in vitro in C26 colon carcinoma (2011-2012).

24- Ensieh Golali, Preparation and physicochemical characterization of nanoliposomes containing Leishmania antigens and PO CpG ODN and the immune response in  murine model (2010-2011).

25- Morteza Akbari, Formulation, characterization and in vivo evaluation of nanoliposomes containing curcumin for the topical treatment of leishmaniasis cutaneous lesion in murine model (2009-2011).

26- Maryam parooie, Preparation, study of physicochemical properties of nanoimmunoliposomes containing Leishmania antigen and evaluation of protection rate and immune response against antigen in murine model (2009-2011).

27- Bent-alhoda Nabavi, Formulation and characterization of nanoliposomal doxorubicin targeted with TAT peptides and in vitro evaluation of their anti tumor effects in mice bearing C26 colon carcinoma tumor (2009-2011).

28- Vahid Heravi shargh, Preparation, study of physicochemical properties of nanoliposomes coencapsulated with Leishmania antigen and CpG oligodeoxynucleotides containing phosphodiester backbone (PO-CpG ODN) and evaluation of protection rate and immune response against antigen in murine model (2009-2010).

29- Seyede Hoda Alavizadeh, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN (2008-2010).


Patents:

1- Inventors: A. Sahebkar, Ali Badiee, M. R. Jaafari, 2015, METHOD AND COMPOSITION FOR TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES, United States Patent Application 20150147383-


Peer Reviewed Journal Publications:

1-S. A. Moosavian, K. Abnous, A. Badiee, M. R. Jaafari, 2016. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model, Colloids and Surfaces B: Biointerfaces, 139,228-236.

2- S. H. Alavizadeh, J. Akhtari, A. Badiee, S. Golmohammadzadeh, M. R. Jaafari, 2015. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models, Expert opinion on drug delivery, 16, 1-12.

3- A. Mehravaran, M. R. Jaafari, S. A. Jalali, A. Khamesipour, M. Tafaghodi, M. Hojatizade, A. Badiee, 2015. The role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c mice, Nanomedicine J., 4, 249-260.

4- L. Arabi, A. Badiee, F. Mosaffa, M. R. Jaafari, 2015. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin, J Control. Release, 220, 275-286.

5- M. Amin, M. Mansourian, G. A. Koning, A. Badiee, M. R. Jaafari, T. L.M. ten Hagen, 2015. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region, J Control. Release, 220, 308-315.

6- A. R. Nikpoor, J. Tavakkol-Afshari, Z. Gholizadeh, K. Sadri, M. H. Babaei, J. Chamani, A. Badiee, S. A. Jalali, M. R. Jaafari, 2015. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model, Int. J. Pharm., 495 (1), 162-170.

7- M. Teymouri, H. Farzaneh, A. Badiee, S. Golmohammadzadeh, K. Sadri, M. R. Jaafari, 2015. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma, Eur. J. Pharm. Sci., doi:10.1016/j.ejps.2015.08.011

8- S. A. Moosavian, M. R. Jaafari, S. M. Taghdisi, F. Mosaffa, A. Badiee, K. Abnous, 2015. Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX, Iran J Basic Med Sci., 18(6), 576-586.

9- S. Shariat, A. Badiee, S. A. Jalali, M. Mansourian, S. A. Mortazavi, M. R. Jaafari, 2015. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects, Iran J Basic Med Sci., 18(5), 506-513.

10- A. Sahebkar, A. Badiee, M. Hatamipour, M. Ghayour-Mobarhan, M. R. Jaafari, 2015. Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia, Colloids Surf B Biointerfaces., 129, 71-78.

11- M. Nourbakhsh, M. R. Jaafari, H. Lage, K. Abnous, F. Mosaffa, A. Badiee, J. Behravan, 2015. Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer, Iran J Basic Med Sci., 18(4), 385-392.

12- M. Nourbakhsh, J. Behravan, H. Lage, K. Abnous, F. Mosaffa, A. Badiee, M. R. Jaafari, 2015. Nanolipoparticles-mediated MDR1 siRNA delivery: preparation, characterization and cellular uptake, Nanomedicine journal, 2(1), 39-45.

13- F. Eskandari, G. A. Talesh, M. Parooie, M. R. Jaafari, A. Khamesipour, Z. Saberi, A. Abbasi, A. Badiee, 2014. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of Leishmaniasis, Exp. Parasitol., 146, 78-86

14- S. Shariat, A. Badiee, S. A. Jalali, M. Mansourian, M. Yazdani, S. A. Mortazavi, M. R. Jaafari, 2014. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer, Cancer Lett., 355, 54-60.

15- A. Sahebkar, A. Badiee, M. Ghayour-Mobarhan, S. R. Goldouzian, M. R. Jaafari, 2014. A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes, Colloids Surf B Biointerfaces., 122, 645-652.

16- M. Mansourian, A. Badiee, S. A. Jalali, S. Shariat, M. Yazdani, M. Amin, M. R. Jaafari, 2014. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN, Immunol Lett., 162 (1), 87-93.

17- S. H., Alavizadeh, A. Badiee, S. Golmohammadzadeh, M. R. Jaafari, 2014. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma, Int J Pharm.,  473, 326-333.

18- S. Shariat, A. Badiee, M. R. Jaafari, S. A. Mortazavi, 2014. Optimization of a method to prepare liposomes containing HER2/neu- derived peptide as a vaccine delivery system for breast cancer, Iran J Pharm Res., 13, 15-25.

19- M. Amin, A. Badiee, M. R. Jaafari, 2013. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas, Int J Pharm., 458, 324-333.

20- H. Firouzmand, A. Badiee, A. Khamesipour, V. H. Shargh, H. Alavizadeh, A. Abbasi, M. R. Jaafari, 2013. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA), Acta Tropica, 128, 528-535.

21- O. Chavoshian, N. Biari, A. Badiee, A. Khamesipour, A. Abbasi, Z. Saberi, S. A. Jalali, M. R. Jaafari, 2013. Sphingomyelin liposomes containing soluble Leishmania major antigens induced strong Th2 immune response in BALB/c mice, Iran J Basic Med Sci., 16, 965-972.

22- H. Hoseinjani, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, A. Badiee, 2013. Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN, Nanomedicine Journal, 1, 30-40.

23- A. Badiee, V. H. Shargh, A. Khamesipour, M. R. Jaafari, 2013, Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends, Vaccine, 31, 735-749, Review article.

24- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Samiei, D. Soroush, V. H. Shargh, M. Tavassoti Kheiri, F. Barkhordari, W. R. Mc Master, F. Mahboudi, 2012. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen, Experimental Parasitology, 132, 403–409.

25- E. Golali, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, A. Badiee, 2012. Comparison of in vivo adjuvanticity of liposomal PO CpG ODN with liposomal PS CpG ODN: leishmaniasis as a model, Iranian Journal of Basic Medical Sciences, 15, 1032-1045.

26- H. Alavizadeha, A. Badiee, A. Khamesipour, S. A. Jalali, H. Firouzmand, A. Abbasi, M. R. Jaafari, 2012. Evaluation of lesion development and type of immune response generated in BALB/c mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN, Experimental Parasitology, 132, 313-319.

27- V. H. Shargh, M. R. Jaafari, A. Khamesipour, I. Jaafari, S. A. Jalali, A. Abbasi, A. Badiee, 2012. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis, Vaccine, 30, 3957-3964.

28- V. H. Shargh, M. R. Jaafari, A. Khamesipour, S. A. Jalali, H. Firouzmand, A. Abbasi, A. Badiee, 2012. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis, Parasitology Research, 111, 105-114.

29- H. Hejazi, M. Tasbihi, M. R. Jaafari, A. Badiee, N. Pestechian, A. Javadi, A. Khamesipour, 2010. The role of liposomal CpG ODN on the course of L. major infection in BALB/c mice, Iranian J Parasitol, 5(1), 47-54.

30- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Samiei, D. Soroush, M. T. Kheiri, F. Barkhordari, W. R. McMaster, F. Mahboudi, 2009. The role of liposome charge on immune response generated in BALB/c mice immunized with rgp63, Experimental Parasitology, 121, 362-369.

31- A. Badiee, M. R. Jaafari, A. Khamesipour, 2009. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition, Colloids and Surfaces B: Biointerfaces, 74(1), 37-44.

32- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, A. Khamesipour, 2008. Co-encapsulation of CpG ODN with rLmSTI1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice, Clinical and Vaccine Immunology, 15, 668-674.

33- A. Badiee, N. M. Davies, K. McDonald, K. Radford, H. Michiue, D. N. J. Hart, M. Kato, 2007. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205, Vaccine, 25, 4757–4766.

34- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush; M. T. Kheiri, F. Barkhordari, A. Khamesipour, W. R. McMaster, F. Mahboudi, 2007. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome, Vaccine, 25, 6107–6117.

35- A. Badiee, M. R. Jaafari, A. Khamesipour, 2007. Leishmania major: Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes, Experimental Parasitology, 115, 127-134.

36- Y. Sohrabi, M. R. Jaafari, A. Badiee, S. H. Hejazi, S. E. Eskandari, A. M. Mohammadi, A. Khamesipour, 2007. Evaluation of immune response against autoclaved Leishmania major incorporated into positively charged liposomes in BALB/c mice, Iranian Journal of Dermatology, 10, 37-53.

37- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, A. Khamesipour, 2006. Immune response evaluation against leishmaniasis using liposomes containing rLmSTI1 in murine model, Iranian Journal of Basic Medical Sciences, 8, 215-225.

38- H. A. Garekani, F. Sadeghi, A. Badiee, S. A. Mostafa, A. R. Rajabi-Siahboomi, 2001. Crystal habit modifications of ibuprofen and their physico-mechanical characteristics, Drug Development and Industrial Pharmacy, 27, 803-809.

39- H. A. Garekani, F. Sadeghi, A. Badiee, 1999, Investigation of the physico-mechanical properties of modified crystals of ibuprofen, Iranian Journal of Basic Medical Sciences, 2, 8-17.


Conference Presentations:

Oral presentations

1- A. Badiee, Lipid-based nanoparticles as vaccine adjuvant and delivery systems: present and future trends, 11th International Congress of Immunology & Allergy (Iran, 2012, Keynote speaker).

2- A. Badiee, M. R. Jaafari, A. Khamesipour, Liposomes as vaccine delivery systems for soluble Leishmania antigens (SLA): where are we today?, 5th Iranian Controlled release Conference (Iran, 2011).

3- A. Badiee,  M. Parooei, M. R. Jaafari A. Khamesipour., Preparation and physicochemical characterization of nanoimmunoliposomes containing SLA as a vaccine against Leishmaniasis, 1st Nanodrugs Congress (Iran, 2011).

4- A. H. Alavizadeh, M. R. Jaafari, A. Badiee, A. Khamesipour, A. Jalali, A. Abbasi, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD Nanoparticles containing CpG ODN, 3rd Conference on Nanostructures (Iran, 2010).

5- A. Badiee, M. R. Jaafari, A. Khamesipour, Formulation, characterization and evaluation of immune response of liposomes containing leishmania antigen and CpG ODN against leishmaniasis in murine model, 4th Iranian Controlled Release Conference (Iran, 2009).

6- A. Badiee, M. Kato, D. N. J. Hart, N. M. Davies, Preparation and characterization of anti-hDEC-205 immunoliposome nanoparticles for targeting to human dendritic cells, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S27.

7- M.R. Jaafari, A. Badiee, A. Khamesipour, A. Samiei, D. Soroush, A. Abbasi, M. Tavassoti Kheiri, F. Barkhordari, F. Mahboudi, Immunization of BALB/c Mice against Leishmaniasisusing LPD nanoparticles containing rgp63 and rLmaCIN prepared with CpG oligodeoxynucleotides, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S41.

8- A. Badiee, M. Kato, D. N. J. Hart, N. M. Davies, Enhanced delivery of anti-hDEC-205 immunoliposomes to human dendritic cells: A strategy for DC-based cancer immunotherapy, 19th Asia Pacific Cancer Conference, (Iran, 2007).

9- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush, A. Khamesipour, M. Amani, F. Mahboudi, Vaccination of BALB/c mice against cutaneous leishmaniasis using liposomes containing rgp63 and CpG ODNs, Third World Congress on Leishmaniosis, (Italy, 2005).

Posters and published Abstracts

1- A. Sahebkar, S.R. Goldouzian, A. Badiee, M. R.  Jaafari. A novel nanoliposomal approach for the treatment of severe hyperlipidemia. Iranian Controlled Release Congress, 2011.

2- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, Preparation and characterization of nanoliposomes containing soluble Leishmania antigens and MPL adjuvant, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S238.

3- F. Mosaffa, M. R.  Jafaari, L. Arabi, A. Badiee, Isolation and identification of putative cancer stem cells in C26 murine colon carcinoma cell line, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S462.

4- M. Bagheri, A. Badiee, M. R. Jaafari, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S214.

5- A. Badiee, M. R. Jaafari, M. R. Amin, Antitumor efficacy of RGD-targeted liposomes containing doxorubicin in mice bearing C-26 colon carcinoma, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S1003.

6- M. Parooei, M. R. Jaafari A. Khamesipour. A. Badiee, Preparation and physicochemical characterization of immunoliposome nanoparticles as a vaccine delivery system: Leishmaniasis as a model, 12th Iranian Congress of Biochemistry & 4th International Congress of Biochemistry & molecular Biology (Iran, 2011), Clinical Biochemistry 44 (13), S216.

7- A. M. Eslahtalab, A. Badiee, Dendritic cells-based cancer vaccines: The role of lipid-based nanoparticles, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S59.

8- H. Alavizadeh, A. Badiee, M. R. Jaafari, Lipid-protamine-DNA (LPD) nanoparticles as a vaccine delivery system for cancer immunotherapy, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S130.

9- M. R. Amin, A. Badiee, M. R. Jaafari, Nanoparticulate systems in cancer detection and therapy, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S155.

10- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush; M. T. Kheiri, F. Barkhordari, A. Khamesipour, F. Mahboudi, The role of liposome charge on immune response generated in BALB/c mice immunized with rgp63, 11th Liposome Research Days Conference, (Japan, 2008).

11- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush, A. Khamesipour, Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition, 3rd ILS Annual Meeting: Liposome Advances, (UK, 2007).

12- A. Badiee, M. R. Jaafari, A. Khamesipour, Immunization of BALB/c mice against cutaneous Leishmaniasis by Leishmania major strees inducible protein 1 encapsulated in liposomes,10th Iranian Pharmaceutical Ssciences Conference, (Iran, 2006).

13- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, J. Webb, A. Khamesipour, Immunization of BALB/c mice against cutaneous leishmaniasis using liposomes containing rLmSTI1 and CpG ODNs, Third World Congress on Leishmaniosis, (Italy, 2005).

14- H. A. Garekani, F. Sadeghi, A. Badiee, A. R. Rajabi-Siahboomi, Crystal habit modifications of ibuprofen and their physico-mechanical characteristics., 19th Pharmaceutical Technology Conference, (Italy, 2000).

15- S. Shojaiee, Y. Sohrabi, A. Badiee, Effect of Gentamycine on stimulation of immune system in rabbit. Proceeding of the 4th congress of Iranian pharmacy students, (Iran, 1997).


Referees:

1- Professor Mahmoud Reza Jaafari:

Ph.D. Thesis supervisor,

School of Pharmacy, Mashhad University of Medical Sciences, Iran

E-mail: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Tel: +985138823255

2- Professor Ali Khamesipour:

Ph.D. Thesis co-supervisor,

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Iran

E-mail: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Tel: +982188970657

3- Professor Derek Hart:

Research fellowship co-supervisor,

C64 - ANZAC Research Institute, The University of Sydney, NSW 2006, Australia

E-mail: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Tel: +61297679822

4- Dr. Nigel Davies:

Research fellowship supervisor,

Pharmaceutical Development, AstraZeneca R&D, Pepparedsleden 1, Mölndal, S-43183, Sweden

E-mail: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Tel: +46317762977

5- Professor Leaf Huang:

Visiting scholar supervisor,

Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, campus box 7571, Chapel Hill, NC 27599-7571, USA

E-mail: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Tel: +19198430736